Pemphigus Clinical Trial
Official title:
Validation of 5-Point Investigator Global Assessments for Pemphigus
This study aims to explore the reliability and validity of newly developed Investigator Global Assessments (IGAs) in scoring the severity of pemphigus. IGAs are simple 5-point scales ranging from clear - severe and are preferred by the FDA as endpoints in clinical trials.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | August 30, 2023 |
Est. primary completion date | August 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Having pemphigus diagnosed by a qualified dermatologist - Aged 18 or older at the time of photography Exclusion Criteria: - Those whose photographs are unable to be adequately de-identified |
Country | Name | City | State |
---|---|---|---|
Australia | Premier Specialists | Kogarah | New South Wales |
Bulgaria | Medical University of Sofia | Sofia | |
Greece | Aristotle University of Thessaloniki | Thessaloníki | |
Iran, Islamic Republic of | Razi Hospital | Tehran | |
Israel | Tel Aviv Medical Centre | Tel Aviv | |
Singapore | National University Hospital of Singapore | Singapore | |
Turkey | Akdeniz University Hospital | Antalya |
Lead Sponsor | Collaborator |
---|---|
Premier Specialists, Australia |
Australia, Bulgaria, Greece, Iran, Islamic Republic of, Israel, Singapore, Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | IGA-PV-M (D/P/F), IGA-PV-S (D/P/F), IGA-PF (D/P/F) | IGA score of pemphigus severity, possible score from 0-4 | Baseline | |
Primary | Pemphigus Disease Activity Index (PDAI) Score | Possible score from 0-263 | Baseline | |
Primary | Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) | Possible score from 0-206 | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00278642 -
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
|
Phase 1 | |
Not yet recruiting |
NCT05898308 -
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
|
Phase 4 | |
Terminated |
NCT01559155 -
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
|
||
Active, not recruiting |
NCT01974518 -
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
|
Phase 3 | |
Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Completed |
NCT00283712 -
Use of Infliximab for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT06285435 -
Coagulation Activation in Patients With Pemphigus
|
||
Not yet recruiting |
NCT06454357 -
A Clinical Study of B007 in the Treatment of Pemphigus.
|
Phase 2/Phase 3 | |
Completed |
NCT01299857 -
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
|
Phase 3 | |
Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
Completed |
NCT00213512 -
Effect of Anti CD20 in Pemphigus Desease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04400994 -
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
|
Phase 2 | |
Recruiting |
NCT02237313 -
Identification of Vulnerability Factors in the Course of Pemphigus Patients
|
N/A | |
Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
Terminated |
NCT03762265 -
A Study of PRN1008 in Patients With Pemphigus
|
Phase 3 | |
Recruiting |
NCT02365675 -
Wound Dressings for Pemphigus and Pemphigoid
|
N/A | |
Recruiting |
NCT01338103 -
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
|
N/A | |
Active, not recruiting |
NCT00656656 -
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
|
Phase 2 | |
Completed |
NCT00127764 -
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
|
Phase 2/Phase 3 |